Markers of Minimal Residual Disease
Current methods employing tumour markers to detect small amounts of residual disease are reviewed with respect to human germ cell, colorectal and breast neoplasms. It is concluded that the assay of tumour markers in body fluids has only limited clinical value. Alternative approaches, such as are afforded by radioimmu nodetection and immunocytochemistry, are presented and critically appraised.
KeywordsIodine Myeloma Nash Teratoma Hine
Unable to display preview. Download preview PDF.
- 8.Kohn J (1979) The value of apparent half-life assay of alpha-1 fetoprotein in the management of testicular teratoma. In: Lehmann FG (ed) Carcinoembryonic proteins, vol 2. Elsevier/North-Holland Biomedical Press, Amsterdam, p 383Google Scholar
- 9.Laurence DJR, Neville AM (1980) Biochemical tests in diagnosis and monitoring of cancer. In: Goldberg DM (ed) Annual review of clinical biochemistry, vol 1. Wiley, New York, p 185Google Scholar
- 14.Raghavan D, Gibbs J, Nogueira Cost R, Kohn J, Orr AH, Barrett A, Peckham MJ (1980) The interpretation of marker protein assays: A critical appraisal in clinical studies and a xenograft model. Br J Cancer [Suppl4] 41:191–194Google Scholar
- 15.Sloane JO, Ormerod MG, Neville AM (to be published) Potential pathological application of immunocytochemical methods to the detection of micrometastases. Cancer Res 40Google Scholar